Fentanyl Pectin Nasal Spray Provides Clinically Meaningful Pain Relief and a More Rapid Onset of Analgesia compared with Immediate-release Morphine Sulphate in Breakthrough Cancer Pain

Citation for published version:

Digital Object Identifier (DOI):
10.1177/0269216310366390

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Early version, also known as pre-print

Published In:
Palliative Medicine

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Fentanyl Pectin Nasal Spray Provides Clinically Meaningful Pain Relief and a More Rapid Onset of Analgesia Compared with Immediate-Release Morphine Sulphate in Breakthrough Cancer Pain

M. Fallon, A. Gatti, A. Davies, E. A. Lux, K. Kumar, R. Galvez, on behalf of the Fentanyl Nasal Spray Study 044 Investigators Group
Breakthrough Cancer Pain (BTCP)

- BTCP affects 60%–95% of all cancer patients with pain\(^1\,\text{–}^3\)
- Although variable, a typical BTCP episode is rapid in onset (median onset to peak pain intensity [PI], 1-3 minutes) and short-lived (median duration, 30-45 minutes)\(^1\,\text{,}^3\)
- Oral immediate-release morphine sulphate (IRMS) is the most common treatment for BTCP. However, its time to effectiveness can be too slow (≥30 minutes) to be consistent with the profile of a typical BTCP episode\(^4\,\text{,}^5\)
- Shortening the time to meaningful pain relief, delivering consistent efficacy, optimising patient acceptability and tolerability are likely to improve treatment outcomes

Optimising BTCP Management

• Conventional nasal products are convenient as simple aqueous solutions delivered as sprays but may not be the most appropriate solution given potential problems with nasal drip and unpredictable drainage from the nose, which may also impact consistency of dosing\(^1\)

• Fentanyl pectin nasal spray (FPNS) has been developed with PecSys\(^\text{®}\) delivery technology to produce a rapid but controlled delivery of fentanyl across the nasal mucosa\(^1\)

• FPNS has been shown to have a rapid onset of effect in BTCP (5 minutes), provide clinically meaningful pain relief (10 minutes) and have consistent efficacy in FPNS-treated episodes compared with placebo\(^2\)

FPNS versus IRMS

Double-blind, double-dummy, randomised controlled trial

• **Primary objective**
  – To demonstrate the superior efficacy of FPNS (100–800 μg) compared with IRMS in the treatment of BTCP in opioid-tolerant cancer subjects
    o Primary clinical end point: pain intensity difference at 15 minutes (PID15)

• **Secondary objectives**
  – To demonstrate the onset of action, time to clinically meaningful PR, acceptability, safety and tolerability of FPNS compared with IRMS
    o Secondary efficacy end points: PI, PID, summed PID, PR
    o Patient acceptability and satisfaction
    o Adverse events (AEs)
    o Tolerability profile
Patient Disposition

- 76% successfully titrated

- Demographics
  - Mean age (±SD): 55.9 ± 12.3
  - 53.8% male; 46.2% female

- 94% completed the double-blind phase of the study

- Only 4.7% of patients withdrew from titration (2.4% in DB/DD phase) due to AEs and 5.5% due to lack of efficacy

- 740 BTCP episodes were analysed (372 treated with FPNS, 368 treated with IRMS)
Primary End Point: PID15

Pain Intensity Difference (mean ± SE)

Time from Dosing (minutes)

*P < 0.05, FPNS vs. IRMS.
**P < 0.01, FPNS vs. IRMS.
Onset of Pain Improvement
(≥1-point change in PR)

*P < 0.05, FPNS vs. IRMS.
**P < 0.001, FPNS vs. IRMS.
Episodes with Clinically Meaningful PR (≥2-Point Reduction in PI\(^1\))

Episodes (%)

<table>
<thead>
<tr>
<th>Time from Dosing (minutes)</th>
<th>FPNS</th>
<th>IRMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>25.3</td>
<td>22.8</td>
</tr>
<tr>
<td>10</td>
<td>52.4</td>
<td>45.4</td>
</tr>
<tr>
<td>15</td>
<td>75.5</td>
<td>69.3</td>
</tr>
</tbody>
</table>

*P < 0.05, FPNS vs. IRMS.

Satisfaction with Nasal Spray

Ease of Use

<table>
<thead>
<tr>
<th>Patients (%)</th>
<th>Not satisfied</th>
<th>Not satisfied or dissatisfied</th>
<th>Satisfied</th>
<th>Very satisfied</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.5</td>
<td>7.6</td>
<td>58.2</td>
<td>19.0</td>
</tr>
</tbody>
</table>

Convenience

<table>
<thead>
<tr>
<th>Patients (%)</th>
<th>Not satisfied</th>
<th>Not satisfied or dissatisfied</th>
<th>Satisfied</th>
<th>Very satisfied</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2.5</td>
<td>5.1</td>
<td>58.2</td>
<td>21.5</td>
</tr>
</tbody>
</table>

*Missing values: 12.7%.*
Acceptability with FPNS

• Higher rating of **overall satisfaction** with FPNS compared with IRMS
  – 30 minutes: 2.9 vs. 2.6, $P < 0.01$
  – 60 minutes: 3.0 vs. 2.7, $P = 0.01$

• Higher rating of **speed of relief** with FPNS compared with IRMS
  – 30 minutes: 2.9 vs. 2.6, $P < 0.01$
  – 60 minutes: 3.0 vs. 2.7, $P < 0.01$

• Higher rating of **reliability** with FPNS compared with IRMS
  – 3.0 vs. 2.7, $P = 0.01$
## Treatment-Related Adverse Events by Severity (all phases, by patient)

<table>
<thead>
<tr>
<th>Severity</th>
<th>FPNS, n (%)</th>
<th>IRMS, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>100 µg n = 105</td>
<td>200 µg n = 82</td>
</tr>
<tr>
<td>Mild</td>
<td>8 (7.6)</td>
<td>6 (7.3)</td>
</tr>
<tr>
<td>Moderate</td>
<td>0 (0)</td>
<td>3 (3.7)</td>
</tr>
<tr>
<td>Severe</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total</td>
<td>8 (7.6)</td>
<td>9 (11.0)</td>
</tr>
</tbody>
</table>

### Treatment-related adverse events
- Typical of opioids
- More frequent with FPNS
- Mainly mild to moderate
- Not dose related
Average nasal symptom score was assessed at 60 minutes after dosing for each episode during the double-blind period. Patients completed a nasal symptom score for 10 symptoms as follows: 0 = absent, 1 = mild, 2 = moderate and 3 = severe. The nasal symptom score was averaged over all episodes treated during the double-blind treatment phase.
Summary and Conclusions

• First clinical study to show the superiority of a new-generation fentanyl-based BTCP product over the most widely used standard treatment, IRMS

• Confirms and extends previous findings that FPNS provides rapid onset of action from as early as 5 minutes after dosing and early clinically meaningful levels of PR from 10 minutes after dosing
  – Significantly greater number of episodes showed improvement in PR scores within 5 minutes compared with IRMS
  – Significantly greater number of episodes treated with FPNS showed clinically meaningful PR (≥2-point reduction in PI) by 10 minutes compared with episodes treated with IRMS
Summary and Conclusions (cont)

• FPNS had significantly higher acceptability and satisfaction scores than did IRMS at both 30 and 60 minutes

• FPNS was safe and well tolerated and resulted in no significant symptoms or clinical findings related to nasal administration

• In conclusion, this study demonstrates superior outcomes with FPNS compared with IRMS in the treatment of BTCP that better match the rapid onset and relatively short duration of the typical BTCP episode